tetano
Editor, Senior Moderator
Ups J Med Sci
. 2021 Dec 10;126.
doi: 10.48101/ujms.v126.8136. eCollection 2021.
The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE)
Rickard Ljung[SUP] 1 [/SUP], Anders Sundström[SUP] 1 [/SUP], Maria Grünewald[SUP] 1 [/SUP], Charlotte Backman[SUP] 1 [/SUP], Nils Feltelius[SUP] 1 [/SUP], Rolf Gedeborg[SUP] 1 [/SUP], Björn Zethelius[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The coronavirus disease 2019 (COVID-19) vaccines have been rapidly implemented in national vaccination programs world-wide after accelerated approval processes. The large population exposure achieved in very short time requires systematic monitoring of safety. The Swedish Medical Products Agency has launched a project platform for epidemiological surveillance to detect and characterise suspected adverse effects of COVID-19 vaccines in Sweden.
Methods: The platform includes all individuals 12 years or older in Sweden in 2021 and will be updated annually. Data, including vaccine and COVID-19 disease data, socioeconomic and demographic data, comorbidity, prescribed medicines and healthcare utilisation outcomes, are obtained from several national registers in collaboration with other Swedish Government agencies. Data from 2015 to 2019 are used as a historical comparison cohort unexposed to both the COVID-19 pandemic and to the COVID-19 vaccines.
Results: The primary study cohort includes 8,305,978 adults 18 years and older permanently residing in Sweden on 31 December 2020. The historical control cohort includes 8,679,641 subjects. By 31 July 2021, around 50% of those 18 years and older and two-thirds of those 50 years and older were vaccinated with at least one dose, 90% of those 70 years or older had two doses.
Conclusions: The nationwide register-based study cohort created by the Swedish Medical Products Agency with regular updates of individual level linkage of COVID-19 vaccination exposure data to other health data registers will facilitate both safety signal detection and evaluation and other pharmacoepidemiological studies.
Keywords: COVID-19; SARS-CoV-2; efficacy; epidemiological; monitoring; pharmacovigilance; safety; signal detection; surveillance; vaccine.
. 2021 Dec 10;126.
doi: 10.48101/ujms.v126.8136. eCollection 2021.
The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE)
Rickard Ljung[SUP] 1 [/SUP], Anders Sundström[SUP] 1 [/SUP], Maria Grünewald[SUP] 1 [/SUP], Charlotte Backman[SUP] 1 [/SUP], Nils Feltelius[SUP] 1 [/SUP], Rolf Gedeborg[SUP] 1 [/SUP], Björn Zethelius[SUP] 1 [/SUP]
Affiliations
- PMID: 34984096
- PMCID: PMC8693580
- DOI: 10.48101/ujms.v126.8136
Abstract
Background: The coronavirus disease 2019 (COVID-19) vaccines have been rapidly implemented in national vaccination programs world-wide after accelerated approval processes. The large population exposure achieved in very short time requires systematic monitoring of safety. The Swedish Medical Products Agency has launched a project platform for epidemiological surveillance to detect and characterise suspected adverse effects of COVID-19 vaccines in Sweden.
Methods: The platform includes all individuals 12 years or older in Sweden in 2021 and will be updated annually. Data, including vaccine and COVID-19 disease data, socioeconomic and demographic data, comorbidity, prescribed medicines and healthcare utilisation outcomes, are obtained from several national registers in collaboration with other Swedish Government agencies. Data from 2015 to 2019 are used as a historical comparison cohort unexposed to both the COVID-19 pandemic and to the COVID-19 vaccines.
Results: The primary study cohort includes 8,305,978 adults 18 years and older permanently residing in Sweden on 31 December 2020. The historical control cohort includes 8,679,641 subjects. By 31 July 2021, around 50% of those 18 years and older and two-thirds of those 50 years and older were vaccinated with at least one dose, 90% of those 70 years or older had two doses.
Conclusions: The nationwide register-based study cohort created by the Swedish Medical Products Agency with regular updates of individual level linkage of COVID-19 vaccination exposure data to other health data registers will facilitate both safety signal detection and evaluation and other pharmacoepidemiological studies.
Keywords: COVID-19; SARS-CoV-2; efficacy; epidemiological; monitoring; pharmacovigilance; safety; signal detection; surveillance; vaccine.